Brigatinib-analog

new

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:Brigatinib-analog is an orally active, potent and selective anaplastic lymphoma kinase (ALK)and the epidermal growth factor receptor (EGFR) inhibitor. Brigatinib-analog is structurally related to Brigatinib (AP-26113). Brigatinib-analog binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells.

Price and Availability

Brigatinib-analog, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 205765Name: Brigatinib-analogCAS#: 1197958-12-5 (analog)Chemical Formula: C26H34ClN6O2PExact Mass: 528.21694Molecular Weight: 529.01Elemental Analysis: C, 59.03; H, 6.48; Cl, 6.70; N, 15.89; O, 6.05; P, 5.85

Related CAS #:1197958-12-5 (analog)1197953-54-0

Synonym:AP26113-analog; AP-26113-analog; AP 26113-analog, Brigatinib-analog

IUPAC/Chemical Name:(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide

InChi Key:OVDSPTSBIQCAIN-UHFFFAOYSA-N

InChi Code:InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)

SMILES Code:CP(C)(C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCC(N(C)C)CC4)C=C3OC)=NC=C2Cl)=O

Technical Data

Additional Information

Brigatinib-Analog was introduced to the research community due to wrong information published in the following well-known resources. the wrong information had been mislead many reagent vendors included MedKoo.

The following resources have published a wrong structure for Brigatinib (AP-26113)

1. Some papers Such as Onco Targets Ther. 2014 Mar 5;7:375-85., http://www.ncbi.nlm.nih.gov/pubmed/24623980 )

2. wikipedia (https://en.wikipedia.org/wiki/Brigatinib, last visited on 12/9/2015).

3. Sci-Finder Scholar Database: Before December 2015,Sci-Finder Scholar Database alsowrongly listed CAS#1197958-12-5 asBrigatinib (AP26113). Now Sci-Finder Scholar Database has corrected.

4. Pubchem: https://pubchem.ncbi.nlm.nih.gov/compound/ap26113

References

1: Rossi A, Maione P, Sacco PC, Sgambato A, CasaluceF, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors andadvanced non-small cell lung cancer (review). Int J Oncol. 2014Aug;45(2):499-508. doi: 10.3892/ijo.2014.2475. Epub 2014 May 29. PubMedPMID: 24889366.

2: Iwama E, Okamoto I, Harada T, Takayama K, Nakanishi Y. Development ofanaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis inALK rearrangement-positive lung cancer. Onco Targets Ther. 2014 Mar5;7:375-85. doi: 10.2147/OTT.S38868. eCollection 2014. Review. PubMedPMID: 24623980; PubMed Central PMCID: PMC3949762.

3: Perez CA, Velez M, Raez LE, Santos ES. Overcoming the resistance tocrizotinib in patients with non-small cell lung cancer harboringEML4/ALK translocation. Lung Cancer. 2014 May;84(2):110-5. doi:10.1016/j.lungcan.2014.02.001. Epub 2014 Feb 8. PubMed PMID: 24598368.

4: Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy foranaplastic lymphoma kinase-rearranged non-small cell lung cancer. ClinPharmacol Ther. 2014 Jan;95(1):15-23. doi: 10.1038/clpt.2013.200. Epub2013 Oct 3. Review. PubMed PMID: 24091716.

5: Yu HA, Riely GJ. Second-generation epidermal growth factor receptortyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013Feb 1;11(2):161-9. PubMed PMID: 23411383; PubMed Central PMCID:PMC3673302.

6: Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C.Crizotinib-resistant NPM-ALK mutants confer differential sensitivity tounrelated Alk inhibitors. Mol Cancer Res. 2013 Feb;11(2):122-32. doi:10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13. PubMed PMID: 23239810.

7: Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM,Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategiesto overcome crizotinib resistance in non-small cell lung cancersharboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.PubMed PMID: 21502504; PubMed Central PMCID: PMC3088626.